A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States

Purpose Alopecia areata (AA) is an autoimmune disease characterized by the development of non-scarring alopecia. The prevalence is not well known, and estimates vary considerably with no recent estimates in the United States (US). The objective of this study was to define the current AA point prevalence estimate among the general population in the US overall and by severity. Patients and Methods We administered an online, cross-sectional survey to a representative sample of the US population. Participants self-screening as positive for AA using the Alopecia Assessment Tool (ALTO) also completed the Severity of Alopecia Tool (SALT) to measure the severity of disease as a percent of scalp hair loss. Self-reported AA participants were invited to upload photographs for adjudication of AA by 3 clinicians. Results The average age of participants was 43 years. Approximately half of the participants (49.2%) were male, and the majority were white (77.1%) and not of Hispanic origin (93.2%). Among the 511 self-reported AA participants, 104 (20.4%) uploaded photographs for clinician evaluation. Clinician-adjudicated point prevalence of AA was 0.21% (95% CI: 0.17%, 0.25%) overall, 0.12% (95% CI: 0.09%, 0.15%) for “mild” disease (≤50% SALT score), and 0.09% (95% CI: 0.06%, 0.11%) for “moderate to severe” disease (>50% SALT score) with 0.04% (95% CI: 0.02%, 0.06%) for the alopecia totalis/alopecia universalis (100% SALT score) “moderate to severe” subgroup. The average SALT score was 44.4% overall, 8.8% for “mild”, and 93.4% for “moderate to severe”. Conclusion This study suggests that the current AA prevalence in the US is similar to the upper estimates from the 1970s at approximately 0.21% (700,000 persons) with the current prevalence of “moderate to severe” disease at approximately 0.09% (300,000 persons). Given this prevalence and the substantial impact of AA on quality of life, the burden of AA within the US is considerable.

[1]  A. Qureshi,et al.  Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO) , 2018, PloS one.

[2]  B. Kahan,et al.  A comparison of approaches for adjudicating outcomes in clinical trials , 2017, Trials.

[3]  S. Farajzadeh,et al.  Clinical and demographic profile of childhood alopecia areata in Iran , 2016 .

[4]  M. Péntek,et al.  Alopecia areata and health‐related quality of life: a systematic review and meta‐analysis , 2016, The British journal of dermatology.

[5]  M. Miteva,et al.  Epidemiology and burden of alopecia areata: a systematic review , 2015, Clinical, cosmetic and investigational dermatology.

[6]  Amrapali Zaveri,et al.  Global burden of skin disease as reflected in Cochrane Database of Systematic Reviews. , 2014, JAMA dermatology.

[7]  C. Amos,et al.  Health-Related Quality of Life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data. , 2013, The journal of investigative dermatology. Symposium proceedings.

[8]  A. Schrum,et al.  Lifetime incidence risk of Alopecia Areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990–2009 , 2013, The Journal of investigative dermatology.

[9]  E. Olsen Investigative guidelines for alopecia areata , 2011, Dermatologic therapy.

[10]  M. Akiyama,et al.  Prevalence of dermatological disorders in Japan: A nationwide, cross‐sectional, seasonal, multicenter, hospital‐based study , 2011, The Journal of dermatology.

[11]  Carrie Kovarik,et al.  Mobile teledermatology in the developing world: implications of a feasibility study on 30 Egyptian patients with common skin diseases. , 2011, Journal of the American Academy of Dermatology.

[12]  K. Kyriakis,et al.  Alopecia areata prevalence by gender and age , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  G. Sethi,et al.  Alopecia areata in the Indian subcontinent. , 2007, Skinmed.

[14]  P. Christos,et al.  Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  S Gustke,et al.  Reliability of dermatology teleconsultations with the use of teleconferencing technology. , 1997, Journal of the American Academy of Dermatology.

[16]  L. Melton,et al.  Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. , 1995, Mayo Clinic proceedings.

[17]  K. Safavi Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. , 1992, Archives of dermatology.

[18]  J. Koo,et al.  PROFILE OF ALOPECIA AREATA: A QUESTIONNAIRE ANALYSIS OF PATIENT AND FAMILY , 1992, International journal of dermatology.

[19]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[20]  Megan Holstein,et al.  Website , 2019, iPhone App Design for Entrepreneurs.

[21]  J. Fleiss Measuring nominal scale agreement among many raters. , 1971 .